Most clinical trials for asthma drugs exclude ~95% of potential subjects and test under highly controlled conditions, limiting their results' generalizability. Price et al publish results of 2 "pragmatic" open-label trials set in the real world. In #1, they randomized 300 symptomatic asthmatics in 53 U.K. primary care clinics to get either a leukotriene receptor antagonist (LTRA) or inhaled steroid as 1st-line therapy for asthma. In the other, 350 were randomized to LTRA or long-acting beta-agonist (LABA) as step-up/add-on therapy for asthma uncontrolled by an inhaled steroid.